Special Issue

RNA Splicing in Cancer and Targeted Therapies

Message from the Guest Editors

Alternative RNA splicing has been highlighted as a critical driver of tumorigenesis in the past few decades. The advancement of high-throughput sequencing has allowed us to identify genome-wide aberrantly spliced genes in tumor versus normal tissues. It is now well-established that splicing dysregulation can affect genes involved in virtually every one of the hallmarks of cancer. Although therapeutic approaches modulating aberrant splicing in several genetic diseases are reaching the clinic, this is still in progress in cancer therapies. Pharmacological inhibition of alternative splicing using small molecules/drugs, and RNA-based therapeutics, have shown promising outcomes in cancer cells. However, there are still many challenges to overcome, such as specificity, potency, toxicity, delivery, off-target effects, drug resistance, etc. In this Special Issue, we welcome manuscripts that can extend our understanding of the mechanisms of cancer-associated alternative splicing, identification of aberrant splicing targets, oncogenic somatic mutations in splicing factors, functional characterization, and development of potential therapeutic strategies targeting splicing.

Guest Editors

Dr. Mohammad Rahman

Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA

Dr. Ledong Wan

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA

Deadline for manuscript submissions

closed (5 July 2023)

GCAT
TACG
GCAT

Genes

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed

mdpi.com/si/109225

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

mdpi.com/journal/genes

MDPI

GCAT
TACG
GCAT

Genes

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed

mdpi.com/journal/genes

MDPI

About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Department of Pathology, The University of Alabama at Birmingham, 1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))